- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02699814
H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation (H3)
The goal of this project is to develop and pilot test a community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems that is replicable, effective, and sustainable. Project procedures include child mental health screening, on-site brief mental health interventions, referral to specialty mental health, use of co-located child psychiatrist, detection of need for primary care in specialty mental health program. Subjects will be enrolled for 1 year, with interviews at baseline and 3, 6 and 12 months.
Dr. Bonnie Zima at UCLA has been contracted by the project funder to design and implement the evaluation of the project, which includes developing data collection procedures, training staff on implementation of data collection workflow, coordinating with sites to ensure evaluation design and IRB protocols are followed, and coordinating with both study sites to verify data reliability.
Some potential anticipated risks include being uncomfortable answering questions associated with the measures used in the study, and although unlikely, someone may access participant information that is confidential. Some benefits include helping to find ways to improve how to deliver mental health care for children served in publicly-funded primary care and mental health clinics.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
UCLA is in charge of the evaluation of the H3 project, including evaluation design and overseeing data collection by project sites. UCLA will receive data collected by each site and perform the analysis of the data for the sites to be shared with the Illinois Children's Healthcare Foundation and clinic sites. This study will evaluate an existing intervention, meaning that participation in the evaluation is not required in order to receive H3 services.
The information below is included in the evaluation design document attached in 10.1, 1.0:
The overarching goal of the Healthy Minds, Healthy Children, Healthy Chicago Initiative (H3) is to develop a community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems that is replicable, effective, and sustainable.
The final study design is a longitudinal cohort study of 400 children ages 0-17 years and their families served at the two intervention clinic sites (n=200/site) The study time points are baseline, 3-, 6-, and 12-months.
The data sources are parent and youth report, and clinic administrative data when feasible for the programs to transfer these data following IRB-approved procedures. The unit of analysis is the child. The main proximal (or short term) clinical outcomes are related to the H3 intervention care processes (e.g., brief mental health interventions, referral to specialty mental health care, co-located child psychiatrist). The time period will likely vary by child depending on clinical need, but it is anticipated that most of these care processes will be provided during the early phase when the child and parent is introduced to the new care model. The main distal outcomes (or more long-term) are clinical improvement (e.g., child symptom reduction, improved functioning) and some correspond to the care process delivered (e.g., if parent receives parent training, improvement parenting skills are assessed). The time points for tracking clinical improvement are 3, 6 and 12 months after the baseline interview that is done when the parent and child are enrolled in the evaluation. The independent variables (or factors that may influence care processes and clinical outcomes) are child sociodemographic characteristics (e.g. age, sex, race/ethnicity), psychosocial complexity, and primary caregiver characteristics that the clinic team or Community Advisory Board deemed relevant (e.g., parenting stress, probable depression). Embedded within the description of a child's psychosocial complexity are indicators of social determinants (e.g. exposure to trauma) that may adversely impact a child's development and well-being.
Findings from this evaluation will provide data on the acceptability and feasibility of the H3 care models, as well as early indicators of whether these care models are promising.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60621
- Miles Square Health Center, Englewood
-
Chicago, Illinois, Соединенные Штаты, 60622
- Erie Family Health Center, West Town
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- between the ages of 0.0-16.99 years
- speaks Spanish or English
- screens positive for a developmental delay or mental health problem
- referral to the H3 care program by a pediatrician based on clinical judgment
- no prior history of receiving any H3 services in the past year
Exclusion Criteria (based on the child's characteristics):
- 17 years old (to avoid reconsent at 12 month follow-up)
- has previously had H3 services in the past year
- can not speak English or Spanish
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Исследования в области здравоохранения
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: H3 Parent/Child Dyads
A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99
years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem.
For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
|
A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
H3 intervention care processes
Временное ограничение: 12 months
|
tracking administration (yes/no) of "brief mental health interventions", "referral to specialty mental health care", "use of co-located child psychiatrist", "detected need for primary care"
|
12 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Mental health functioning
Временное ограничение: Baseline, 3, 6 and 12 months
|
PHQ9
|
Baseline, 3, 6 and 12 months
|
Child development
Временное ограничение: 12 monthsBaseline, 3, 6 and 12 months
|
Pediatric Symptom Checklist
|
12 monthsBaseline, 3, 6 and 12 months
|
Child functioning
Временное ограничение: Baseline, 3, 6 and 12 months
|
Columbia Impairment Scale
|
Baseline, 3, 6 and 12 months
|
Response to trauma and resilience
Временное ограничение: Baseline, 3, 6 and 12 months
|
Traumatic Events Screening Inventory
|
Baseline, 3, 6 and 12 months
|
Care process delivered
Временное ограничение: Baseline, 3, 6 and 12 months
|
Questionnaire administered at baseline, 3, 6, and 12 months asking parent and child about any care processes that he/she received.
|
Baseline, 3, 6 and 12 months
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: Bonnie Zima, MD, MPH, University of California, Los Angeles
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- IRB#15-000757
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Психическое расстройство
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... и другие соавторыАктивный, не рекрутирующийПрофилактические медицинские услуги (PREV HEALTH SERV)Соединенные Штаты
Клинические исследования H3 Services
-
Sanofi Pasteur, a Sanofi CompanyЗавершенный
-
Sanofi Pasteur, a Sanofi CompanyЗавершенныйЗдоровые волонтеры | Иммунизация против гриппаСоединенные Штаты
-
Montefiore Medical CenterBeyond MeatЕще не набирают
-
St. Jude Children's Research HospitalРекрутингГлиобластома | Новообразования центральной нервной системы | Глиома высокой степени злокачественности | Эпендимома | Медуллобластома | Диффузная срединная глиома, H3 K27M-мутант | Атипичная тератоидная/рабдоидная опухольСоединенные Штаты
-
DT MedTech, LLCРекрутингОстеоартроз голеностопного сустава | Посттравматический остеоартроз голеностопного сустава | Остеоартрит голеностопного сустава, вторичный по отношению к воспалительному артриту (нарушение)Соединенные Штаты
-
Beijing Tiantan HospitalРекрутинг
-
UNC Lineberger Comprehensive Cancer CenterЕще не набираютРак поджелудочной железы | Рецидив | Устойчивый к ракуСоединенные Штаты
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.РекрутингРецидивирующий/рефрактерный острый миелоидный лейкозКитай
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...РекрутингB7-H3-положительная рецидивирующая/рефрактерная нейробластомаКитай
-
Second Affiliated Hospital of Soochow UniversitySoochow T-Maximun Biotechnology Co. LTDРекрутингПродвинутая глиома | Осложнения клеточной терапии химерного антигенного рецептора (CAR-T)Китай